Cerebrolysin

Overview

Cerebrolysin is not a single peptide. It is a standardized biological mixture of low-molecular-weight peptides and free amino acids produced by the controlled enzymatic breakdown (proteolysis) of purified porcine (pig) brain proteins. It is manufactured by EVER Pharma (EVER Neuro Pharma, Austria) and supplied as a sterile solution for intravenous infusion or intramuscular injection. The developmental code name FPF-1070 is sometimes used.

Cerebrolysin is approved and marketed in numerous countries across Europe, Asia, and the Commonwealth of Independent States (CIS), where it is positioned as a neurotrophic and neuroprotective agent used adjunctively in stroke, dementia, and brain-injury care. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) through any centralized pathway.

The clinical evidence for Cerebrolysin is mixed and disputed. Some randomized trials and manufacturer-associated meta-analyses report benefits, while independent Cochrane systematic reviews have found no convincing evidence of clinical benefit for acute stroke and only very-low-certainty signals for dementia. This page presents both sides candidly.

Composition

Cerebrolysin is produced from purified porcine brain proteins that are enzymatically digested into a fraction of small biologically active peptides plus free amino acids.

A 2024 analytical study (Seidl & Aigner, Journal of Medicine and Life) compared Cerebrolysin with other "similar" peptide preparations and found that competing generics showed significant variation in peptide fingerprint and biological activity, concluding their manufacturing was "different and non-standardized." The term "Cerebrolysin" thus refers to one manufacturer's specific process, and other porcine brain peptide products are not interchangeable with it.

Proposed mechanism of action

Cerebrolysin's proposed mechanism is neurotrophic: it is hypothesized to mimic or support the action of endogenous neurotrophic factors. Reviews describe it as a "multitarget peptidergic drug with a neurotrophic mode of action." Proposed mechanisms reported in the literature include:

• Neurotrophic mimicry: peptide components are proposed to reproduce signaling associated with brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), supporting neuronal survival and plasticity.
• Neuroprotection: studied in laboratory and animal models for effects on excitotoxicity, oxidative stress, and apoptosis after ischemic or traumatic injury.
• Neurorestoration / plasticity: proposed to support synaptogenesis and neurogenesis in preclinical models.

Much of this mechanistic detail derives from in vitro and animal studies. The extent to which these mechanisms translate into clinically meaningful benefit in humans remains the central, unresolved question.

Clinical evidence

Cerebrolysin has been studied across several neurological indications. The evidence quality and the conclusions differ sharply depending on whether one reads manufacturer-associated trials and meta-analyses or independent Cochrane reviews.

Acute ischemic stroke

The independent Cochrane review (Ziganshina et al., latest update 2023, building on the 2020 version) is the most rigorous synthesis. Across 7 randomized trials and 1,773 participants, it found:

The Cochrane authors concluded that the evidence does not demonstrate clinical benefit of Cerebrolysin for acute ischemic stroke, and flagged a probable increase in non-fatal serious adverse events. This review informed joint European Stroke Organisation / European Academy of Neurology guidance that advises against Cerebrolysin for post-stroke cognitive impairment.

Vascular dementia

The Cochrane review for vascular dementia (Cui et al., 2019; 6 RCTs, 597 participants) found a beneficial signal on cognition (MMSE, ADAS-cog+) and global function, with no difference in adverse-event rates. However, the certainty of this evidence was rated very low because of high risk of bias and heterogeneity. The authors cautioned that "if there are benefits... the effects may be too small to be clinically meaningful" and called for adequately powered, rigorous trials.

Alzheimer's disease

A manufacturer-associated meta-analysis of 6 RCTs (Gauthier et al., 2015, Dementia and Geriatric Cognitive Disorders) reported that Cerebrolysin was significantly better than placebo on cognitive function and global clinical change at 4 weeks (with global benefit persisting at 6 months) and a safety profile comparable to placebo. A 2021 narrative review (Gavrilova & Alvarez, Medicinal Research Reviews) summarized "30 years of clinical use" favorably. These positive syntheses are not independent Cochrane reviews and several involve authors or sponsorship linked to the manufacturer.

Traumatic brain injury (TBI)

Evidence is again mixed. The manufacturer-sponsored CAPTAIN trial series and its prospective meta-analysis (Vester et al., 2021) reported statistically significant superiority of Cerebrolysin on multidimensional outcomes at 30 and 90 days after moderate-to-severe TBI. An independent systematic review (Jarosz et al., 2023, Brain Sciences; 10 studies) reported significant improvement in Glasgow Coma Scale and Glasgow Outcome Scale scores but no significant effect on mortality or length of stay, and noted substantial heterogeneity and a lack of large randomized trials.

Safety and reported effects

In trials, Cerebrolysin is generally described as well tolerated, with adverse-event rates often reported as similar to placebo. Reported effects, where noted, include injection-site reactions, dizziness, agitation, sweating, and (uncommonly) headache or hypersensitivity reactions.

The most important independent safety signal comes from the Cochrane stroke review, which found a probable increase in non-fatal serious adverse events (moderate certainty), even though all-cause death and total SAEs showed little to no difference. Because the preparation is porcine-derived, theoretical concerns about hypersensitivity and animal-source biological material are also relevant. None of the above is medical advice; use of Cerebrolysin, where legal, is a clinical decision.

Regulatory status

Cerebrolysin is reported to be authorized in dozens of countries, but these approvals were granted by different agencies, at different times, and under different evidentiary standards than current FDA or EMA centralized review would require. Its absence from FDA and EMA centralized approval is a key fact often glossed over in promotional material.

Controversy and evidence quality

The Cerebrolysin evidence base is genuinely contested:

• Sponsor involvement. The Cochrane stroke review noted that the manufacturer (EVER Neuro Pharma) supported multiple multicenter trials, fully or by providing drug and placebo, randomization codes, research grants, or statisticians, and the reviewers judged some studies at high risk of bias partly on that basis.
• Methodological limitations. Independent reviews repeatedly cite high attrition, unclear allocation concealment, retrospective protocol registration, heterogeneity, and reliance on older trials.
• Geographic / guideline divergence. Cerebrolysin remains recommended in some national (e.g., Russian) guidelines while European stroke guidance advises against it — a divergence the Cochrane authors explicitly highlighted.
• Published rebuttals. Cochrane's negative stroke conclusions prompted critical responses, including a competing meta-analysis, particularly in Russian-language academic literature.

The honest summary: Cerebrolysin may have benefit in some indications, but the highest-quality independent evidence does not establish a clinically meaningful benefit for acute stroke, and supports only very-low-certainty signals elsewhere.

How it compares

Cerebrolysin differs fundamentally from the other neuropeptides on this site: it is not a single peptide but a standardised porcine-brain peptide mixture, and unlike research chemicals such as Semax, Selank or DSIP, it is an approved, marketed product in many countries (though not by the FDA or EMA). The trade-off is that its clinical evidence is actively disputed: independent Cochrane reviews have not confirmed benefit for stroke. So it has more regulatory standing than the synthetic single-peptides here, but its real-world efficacy is more contested, not less. See the Cognition, mood & sleep overview.

Common misconceptions

• "Cerebrolysin is a peptide." It is a mixture of many peptides and free amino acids, not a single defined peptide with a sequence.
• "It's FDA/EMA-approved because it's sold widely." It is not FDA- or EMA-approved (centrally). Wide international marketing reflects different national decisions and standards, not U.S./EU centralized approval.
• "The clinical benefit is proven." Independent Cochrane reviews do not demonstrate clinical benefit for acute stroke and rate dementia evidence as very-low-certainty. Many positive analyses are manufacturer-associated.
• "All porcine brain peptide products are equivalent to Cerebrolysin." Analytical work shows competing preparations differ substantially in peptide profile and biological activity; they are not interchangeable.
• "It has a known half-life / dose-response like a normal drug." As a heterogeneous mixture, it has no single molecular weight or pharmacokinetic profile.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against primary sources rather than taken at face value.

Verified additions

• A small phase II RCT has tested Cerebrolysin in ALS. As an add-on to riluzole, the ALS Functional Rating Scale–Revised (ALSFRS-R) improved by 2.3 points at one month versus a 0.9-point decline on placebo (P=0.005), with the signal persisting to three months. [Human] The trial was very small and single-centre (n=18), so this is preliminary, not confirmatory (Firstenfeld et al., Journal of Medicine and Life 2023).
• The pooled safety picture is genuinely contested, not one-sided. A manufacturer-adjacent meta-analysis of 12 stroke RCTs (2,202 patients) found no significant difference in serious adverse events between Cerebrolysin and placebo (RR 0.99) [Human] (Strilciuc et al., Pharmaceuticals 2021) — the opposite of the Cochrane stroke review's probable increase in non-fatal serious adverse events (RR 2.39). Both are real; the disagreement itself is the honest takeaway.
• The "neuroinflammation drives neurodegeneration" premise he opens with is real. Misfolded proteins activate microglia and trigger an innate immune response that contributes to Alzheimer's progression and severity. [Human — review] (Heneka et al., Lancet Neurology 2015). This is established neurobiology — but it is background, not evidence that Cerebrolysin corrects it in humans.
• The prevention angle rests on legitimate, evidence-based data. Around 40% of dementia worldwide is associated with 12 modifiable risk factors (hypertension, diabetes, physical inactivity, smoking, excess alcohol, hearing loss, depression, social isolation, obesity, low education, air pollution, head injury). [Human] (Livingston et al., Lancet 2020, 2020 Commission update). This case stands on its own and does not depend on any peptide.

Claims that don't hold up

• "Cerebrolysin delivers the actual neurotrophic factors — BDNF, NGF, GDNF, CNTF — in their natural active configurations." No. Intact neurotrophins (~26 kDa dimers) are far too large to survive the enzymatic hydrolysis that produces Cerebrolysin, whose defining feature is a fraction of peptides below ~10 kDa plus free amino acids. It is proposed to mimic neurotrophic signalling — not to contain those proteins. [Established composition fact] (see Composition above; Seidl & Aigner, Journal of Medicine and Life 2024).
• "A 2015 RCT showed Cerebrolysin cut levodopa to zero and modified Parkinson's disease." No such trial resolves to a real source. Cerebrolysin's published Parkinson's data are limited to small EEG/electrophysiology studies; no randomized trial demonstrates elimination of levodopa or disease modification. This appears misattributed or overstated. [No primary source found]
• "It reverses cortical atrophy and regrows brain tissue." Overstated. MRI volumetry in Alzheimer's trials has, at most, shown a reduced rate of atrophy — not regrowth — and the highest-quality independent synthesis finds no clear clinical benefit for stroke and only very-low-certainty signals for dementia (Ziganshina et al., Cochrane 2023; Cui et al., Cochrane 2019). "Reversal" is not established. [Human]
• "50 years of use — exceptionally benign, with no long-term detrimental effects." Overstated. The independent 2023 Cochrane stroke review found a probable increase in non-fatal serious adverse events (RR 2.39, moderate certainty; Ziganshina et al., 2023). That a manufacturer-adjacent meta-analysis found no such increase (RR 0.99) does not make the record "exceptionally benign" — it makes it contested. [Human]
• "The 2017 Lancet Commission found 12 risk factors accounting for ~50% of dementia." Numbers off. The 2017 commission listed 9 factors (~35%); the 12-factor, ~40% figure comes from the 2020 update (Livingston et al., Lancet 2020). The real headline is ~40%, not 50%. [Human]
• "Alzheimer's was formally reclassified as 'type 3 diabetes' in 2012." Misdated and overstated. The type-3-diabetes framing is de la Monte & Wands, Journal of Diabetes Science and Technology 2008 — and it is a hypothesis / evidence review, not a formal disease reclassification. [Hypothesis]

Frequently asked questions

Can Cerebrolysin repair or regrow a damaged brain?

This is overstated. The strongest independent evidence — Cochrane systematic reviews — finds no clear clinical benefit for acute ischemic stroke and only very-low-certainty signals for dementia. [Human] MRI studies in Alzheimer's have at most shown a slower rate of atrophy, not regrowth of lost tissue, and no randomized trial demonstrates that Cerebrolysin restores lost brain function. Claims that it "rebuilds" or "regrows" the brain go beyond what the data support (Ziganshina et al., Cochrane 2023; Cui et al., Cochrane 2019).

Does Cerebrolysin reverse Alzheimer's, dementia or Parkinson's?

No high-quality evidence shows reversal. A manufacturer-associated meta-analysis reported cognitive and global benefit in mild-to-moderate Alzheimer's (Gauthier et al., 2015), but the independent Cochrane vascular-dementia review rated its beneficial signal as very-low-certainty and cautioned any effect "may be too small to be clinically meaningful." [Human] For Parkinson's, the published human data are limited to small electrophysiology studies — no randomized trial shows disease reversal or elimination of standard medication. [Human]

Is Cerebrolysin approved by the FDA?

No. Cerebrolysin is not approved by the FDA or the EMA through any centralized pathway, and it is not legally marketed in the United States. It is approved and sold in dozens of countries across Europe, Asia and the CIS — but those approvals were granted by different agencies under different evidentiary standards, and wide international sales are not the same as US or EU centralized approval.

Does "50 years of use" mean Cerebrolysin is completely safe?

Longevity of use is not the same as proven safety, and the record is contested rather than clean. The independent 2023 Cochrane stroke review found a probable increase in non-fatal serious adverse events (RR ~2.39, moderate certainty), while a manufacturer-adjacent meta-analysis found no such increase (RR ~0.99). [Human] Because the preparation is porcine-derived, hypersensitivity is a recognised risk rather than merely theoretical — allergic reactions are listed among its adverse effects and rare cases of anaphylaxis have been reported. [Human] It is generally described as well tolerated in trials, but "exceptionally benign with no long-term detrimental effects" overstates a genuinely disputed picture.

Does Cerebrolysin actually contain BDNF, NGF and other neurotrophic factors?

No. Intact neurotrophins such as BDNF and NGF are roughly 26 kDa proteins (as their active dimers) — far too large to survive the enzymatic hydrolysis that defines Cerebrolysin, whose active fraction is peptides below ~10 kDa plus free amino acids. [Established composition fact] It is proposed to mimic neurotrophic signalling, not to deliver those proteins in "natural active form" (Seidl & Aigner, Journal of Medicine and Life 2024).

Should I stack Cerebrolysin with BPC-157 or other peptides for brain repair?

Popular "brain-repair stacks" combining Cerebrolysin with BPC-157, GHK-Cu, Alpha-GPC or others rest on mechanistic extrapolation, not human trials — no randomized study has tested these combinations for cognition or neurodegeneration. [Hypothesis] This page is educational and does not provide protocols, doses, or guidance on combining compounds; where Cerebrolysin is used at all, that is a clinical decision.